Cargando…

A case report of severe adverse reaction of exenatide: Anaphylactic shock

Anaphylactic shock is the severe state of the allergic reaction, which is rapid in onset and fatal. This is the first study that discusses the anaphylactic shock of exenatide reexposure in the patient who has interrupted exenatide treatment. PATIENT CONCERNS: A 47-year-old man was treated with exena...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xujing, Zhai, Aihua, Zhang, Bai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524889/
https://www.ncbi.nlm.nih.gov/pubmed/36181058
http://dx.doi.org/10.1097/MD.0000000000030805
_version_ 1784800588278530048
author Liu, Xujing
Zhai, Aihua
Zhang, Bai
author_facet Liu, Xujing
Zhai, Aihua
Zhang, Bai
author_sort Liu, Xujing
collection PubMed
description Anaphylactic shock is the severe state of the allergic reaction, which is rapid in onset and fatal. This is the first study that discusses the anaphylactic shock of exenatide reexposure in the patient who has interrupted exenatide treatment. PATIENT CONCERNS: A 47-year-old man was treated with exenatide owing to high blood glucose and obesity. Then he developed localized urticarial on the face, white lip, hands tremble, nausea, vomit, chest stuffiness, dizziness, accompanying with confusion and dyspnea. His blood glucose was 4.6 millimole per liter (mmol/L) and blood pressure was 85/50 millimeters of mercury (mm Hg). DIAGNOSIS: Exenatide-induced anaphylactic shock was considered. INTERVENTIONS: The emergency electrocardiogram was performed. The patient was treated with dexamethasone sodium phosphate and calcium gluconate, combined with exenatide withdrawal. He also received oral antiallergic agents and intravenous nutrition treatment. OUTCOMES: After antishock treatment, the clinical response gradually alleviated. LESSONS: Although exenatide is not prone to anaphylaxis, it is the synthetic peptide that can induce antibody formation. Exenatide has immunogenicity with the potential to elicit an allergic reaction upon administration. Clinicians should always pay more attention to the anaphylactic shock of exenatide, when prescribing for diabetics.
format Online
Article
Text
id pubmed-9524889
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-95248892022-10-03 A case report of severe adverse reaction of exenatide: Anaphylactic shock Liu, Xujing Zhai, Aihua Zhang, Bai Medicine (Baltimore) Research Article Anaphylactic shock is the severe state of the allergic reaction, which is rapid in onset and fatal. This is the first study that discusses the anaphylactic shock of exenatide reexposure in the patient who has interrupted exenatide treatment. PATIENT CONCERNS: A 47-year-old man was treated with exenatide owing to high blood glucose and obesity. Then he developed localized urticarial on the face, white lip, hands tremble, nausea, vomit, chest stuffiness, dizziness, accompanying with confusion and dyspnea. His blood glucose was 4.6 millimole per liter (mmol/L) and blood pressure was 85/50 millimeters of mercury (mm Hg). DIAGNOSIS: Exenatide-induced anaphylactic shock was considered. INTERVENTIONS: The emergency electrocardiogram was performed. The patient was treated with dexamethasone sodium phosphate and calcium gluconate, combined with exenatide withdrawal. He also received oral antiallergic agents and intravenous nutrition treatment. OUTCOMES: After antishock treatment, the clinical response gradually alleviated. LESSONS: Although exenatide is not prone to anaphylaxis, it is the synthetic peptide that can induce antibody formation. Exenatide has immunogenicity with the potential to elicit an allergic reaction upon administration. Clinicians should always pay more attention to the anaphylactic shock of exenatide, when prescribing for diabetics. Lippincott Williams & Wilkins 2022-09-30 /pmc/articles/PMC9524889/ /pubmed/36181058 http://dx.doi.org/10.1097/MD.0000000000030805 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liu, Xujing
Zhai, Aihua
Zhang, Bai
A case report of severe adverse reaction of exenatide: Anaphylactic shock
title A case report of severe adverse reaction of exenatide: Anaphylactic shock
title_full A case report of severe adverse reaction of exenatide: Anaphylactic shock
title_fullStr A case report of severe adverse reaction of exenatide: Anaphylactic shock
title_full_unstemmed A case report of severe adverse reaction of exenatide: Anaphylactic shock
title_short A case report of severe adverse reaction of exenatide: Anaphylactic shock
title_sort case report of severe adverse reaction of exenatide: anaphylactic shock
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524889/
https://www.ncbi.nlm.nih.gov/pubmed/36181058
http://dx.doi.org/10.1097/MD.0000000000030805
work_keys_str_mv AT liuxujing acasereportofsevereadversereactionofexenatideanaphylacticshock
AT zhaiaihua acasereportofsevereadversereactionofexenatideanaphylacticshock
AT zhangbai acasereportofsevereadversereactionofexenatideanaphylacticshock
AT liuxujing casereportofsevereadversereactionofexenatideanaphylacticshock
AT zhaiaihua casereportofsevereadversereactionofexenatideanaphylacticshock
AT zhangbai casereportofsevereadversereactionofexenatideanaphylacticshock